Can the Cochlear share price go even higher?

The Cochlear Limited (ASX:COH) share price was a strong performer on Tuesday but could go even higher according to one leading broker…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On Tuesday the Cochlear Limited (ASX: COH) share price was one of the best performers on the S&P/ASX 200 index with a gain of almost 8%.

Investors were fighting to get hold of the hearing solutions company's shares after it announced the launch of the Nucleus Profile Plus Series cochlear implant.

This implant has been designed for routine 1.5 and 3 Tesla magnetic resonance imaging scans without the need to remove the internal magnet.

Management advised that its commercial availability will commence in Germany, with other European countries to follow in the near term. After which, the product will be launched across other developed markets over the coming months, subject to the timing of regulatory approvals.

The market appears to believe this product has the potential to give its top line and real boost and seized on recent share price weakness to pick up shares yesterday.

Is it too late to invest?

I don't believe it is too late to invest and feel Cochlear would be a great long term investment due to the ageing population tailwind, its high quality products, and its global distribution.

One broker which agrees that it isn't too late to invest is Goldman Sachs.

According to a note out of the investment bank this morning, its analysts have upgraded Cochlear's shares to a buy rating and lifted the price target on them to $197.00 from $173.00.

Even after yesterday's stellar gain, this price target implies potential upside of 9% over the next 12 months excluding dividends.

Why is Goldman bullish on Cochlear?

Goldman is bullish on Cochlear due to is leading share in "a structural growth market which is characterized by attractive demographics, relatively favourable pricing, substantial penetration upside and high barriers to entry."

In addition to this, the launch of the Nucleus Profile Plus Series cochlear implant has led to the broker upgrading its growth forecasts by 4% in FY 2020 and 5% in FY 2021.

Goldman now expects earnings per share of $5.29 in FY 2020 and $5.98 in FY 2021. This will be annual growth of just over 13% for both years.

Should you invest?

I think Goldman is spot on with its recommendation and believe Cochlear would be a great investment along with fellow healthcare stars CSL Limited (ASX: CSL) and ResMed Inc (ASX: RMD).

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »